Scientific and clinical progress together with the development of effective novel therapeutic
options has engendered multiple important changes in the diagnosis and management of …

This is an update to the 2014 Canadian Hereditary Angioedema Guideline with an
expanded scope to include the management of hereditary angioedema (HAE) patients …

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and
effective therapy are critical. This revision and update of the global WAO/EAACI guideline on …

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and
appropriate therapy are essential. This update and revision of the global guideline for HAE …

Angioedema is defined as localized and self‐limiting edema of the subcutaneous and
submucosal tissue, due to a temporary increase in vascular permeability caused by the …

Angioedema is defined as local, noninflammatory, self-limiting edema that is circumscribed
owing to increased leakage of plasma from the capillaries located in the deep layers of the …

Hereditary angioedema (HAE) is a disease which is associated with random and often
unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa …

Hereditary angioedema (HAE) is a rare autosomal dominant disease that commonly
manifests with episodes of cutaneous or submucosal angioedema and intense abdominal …

Three types of hereditary angioedema (HAE) have been described: two are due to C1
inhibitor (C1-INH) deficiency (C1-INH-HAE types I and II) and one is characterized by normal …

In the vast majority of patients with hereditary angioedema (HAE), angioedema attacks are
due to the quantitative or functional deficiency of C1-esterase inhibitor (C1-INH), which …